孟枭 孟

- Leading cross-department AI team, developing and deploying proprietary algorithms/models for end-to-end AI workflow for synthetic biology; - State-of-art 3rd models for protein engineering, including LigandMPNN/ESM/RFAA/Chai/etc.; - Machine learning based catalytic transition state modeling using public and proprietary biocatalysis big data; - Enzyme discovery algorithm based on searching/comparing catalytic transition state structureof enzyme-ligand complex; - Identifying key residues for organic-solve tolerance, thermostatbility, stereospecificity and substrate specificity based on machine learning of dynamic structure data; - Virtual iterated typical mutagenesis protocal for fully dry chemistry prediction of combinatorial mutations; - Route design of biosynthesis or multi enzyme cascading; - AI-enabled development of key steps of Rosavin/Bukuchiol biosynthesis, specific enzymatic cutting of biosynthesized Semaglutide polymer, specific enzymatic ligation of Inclisiran motifs, biosynthesis of Ruxotinib/Effinconazole/Indoxacarb/etc.

- Operating/managing RD team of 40+ scientists, end to end biocatalysis capabilities, including high-throughput screening, enzyme evolution, biotransformation process development, fermentation and intermediate/API biosynthesis manufacture - Biosynthesis route and manufacture (preclinical to commercial stage), 30 patents - 20 types of popular industrial available biotransformation (oxido/reductases, transferases, hydrolases, lyases, etc.) and biosynthesis of new modalities. - Bioinformatics AI/cloud platform enabling ultra high-speed enzyme evolution within 4 weeks

- Bioinformatics AI, designing, hardware construction/configuration, data washing, modeling, training and coding - 100% winning in 18 rounds of man-AI battle, 50~70% wet chem reduce using AI - 4 patents + 4 software copyright

- Technical transfer from the strategic collaboration partner Codexis (in Shanghai, Chongqing and Redwood City, CA, US) - Design/construction Porton's first lab & team with end-to-end biocatalysis capability - 50 biosynthesis route and manufacture

- Design/construction WuXi-STA's first lab & team with end-to-end biocatalysis capability - 120 biosynthesis route and manufacture (preclinical to commercial stage) - Enzyme immobilization (commercial scale) - Enzyme library construction (commercial/proprietary), 10 reaction types - 10 patents

国家奖学金，浙江大学优秀研究生

人民奖学金，天津大学优秀毕业论文